ReviewJournal of magnetic resonance imaging : JMRI2026
Emerging Role of MRI-Based Artificial Intelligence in Individualized Treatment Strategies for Hepatocellular Carcinoma: A Narrative Review.
Review in Journal of magnetic resonance imaging : JMRI, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Review of systemic therapy in HCC with an approach to response assessment in clinical practice.Abdominal radiology (New York) · 2026Review
- Artificial Intelligence in the Diagnosis and Prognostic Stratification of Hepatocellular Carcinoma: Current Evidence, Clinical Applications, and Future Perspectives.Biomedicines · 2026Review
- Emerging Role of MRI-Based Artificial Intelligence in Individualized Treatment Strategies for Hepatocellular Carcinoma: A Narrative Review.Journal of magnetic resonance imaging : JMRI · 2026Review
- Application of artificial intelligence in hepatology.Frontiers in digital health · 2026Review
- Multidisciplinary Team (MDT)-Based Approaches for Liver Cancer Treatment: A Discussion Paper on Tumor Boards and Beyond.Journal of multidisciplinary healthcare · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) is the most common subtype of primary liver cancer, with significant variability in patient outcomes even within the same stage according to the Barcelona Clinic Liver Cancer staging system. Accurately predicting patient prognosis and potential treatment response prior to therapy initiation is crucial for personalized clinical decision-making. This review focuses on the application of artificial intelligence (AI) in magnetic resonance imaging for guiding individualized treatment strategies in HCC management. Specifically, we emphasize AI-based tools for pre-treatment prediction of therapeutic response and prognosis. AI techniques such as radiomics and deep learning have shown strong potential in extracting high-dimensional imaging features to characterize tumors and liver parenchyma, predict treatment outcomes, and support prognostic stratification. These advances contribute to more individualized and precise treatment planning. However, challenges remain in model generalizability, interpretability, and clinical integration, highlighting the need for standardized imaging datasets and multi-omics fusion to fully realize the potential of AI in personalized HCC care. Evidence level: 5. Technical efficacy: 4.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.